New formulations of stimulants for attention-deficit hyperactivity disorder: Therapeutic potential

New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant...

Full description

Saved in:
Bibliographic Details
Published in:CNS drugs 2004-01, Vol.18 (14), p.1011-1030
Main Authors: CONNOR, Daniel F, STEINGARD, Ronald J
Format: Article
Language:English
Subjects:
Adult and adolescent clinical studies
Attention Deficit Disorder with Hyperactivity - drug therapy
Attention Deficit Disorder with Hyperactivity - psychology
Biological and medical sciences
Central Nervous System Stimulants - chemistry
Central Nervous System Stimulants - pharmacokinetics
Central Nervous System Stimulants - therapeutic use
Child
Clinical Trials as Topic
Delayed-Action Preparations
Humans
Medical sciences
Methylphenidate - chemistry
Methylphenidate - pharmacokinetics
Methylphenidate - therapeutic use
Neuropharmacology
Personality disorders
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Stereoisomerism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one immediate release and four longer-acting preparations) that have recently become available for the treatment of ADHD. While the therapeutic potential of immediate-release enantiomers of methylphenidate has not yet been clinically realised, new long-acting formulations of stimulants have changed the standard of care for children, adolescents and adults with ADHD. The longer duration of action of these once-daily compounds, and the consequent expansion of the duration of daily ADHD coverage afforded by them, has introduced the realistic possibility of reducing the overall daily burden of ADHD on affected individuals. Although more expensive, these new stimulant formulations are easier for patients to use than older stimulants, more resistant to abuse and misuse, and allow for increased privacy of ADHD treatment at school or work.
ISSN:1172-7047
1179-1934
DOI:10.2165/00023210-200418140-00005